Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Liz J. Hernandez Borrero"'
Autor:
Lindsey Carlsen, Kelsey E. Huntington, Lanlan Zhou, Christoph Schorl, Liz J. Hernandez-Borrero, Aakash Jhaveri, Wafik S. El-Deiry, Shengliang Zhang
Publikováno v:
Oncotarget
Colorectal cancer (CRC) caused over 900,000 deaths worldwide in 2020. A majority of late-stage CRC patients are treated with 5-fluorouracil (5-FU) combined with either irinotecan (CPT-11), oxaliplatin, or both. Despite their widespread use, the mecha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76c8e77b77c200ae86260458ee21bcf1
https://doi.org/10.18632/oncotarget.28075
https://doi.org/10.18632/oncotarget.28075
Autor:
Xiaobing Tian, John Santiago, Nagib Ahsan, Wafik S. El-Deiry, Lanlan Zhou, Jennifer A. Sanders, Liz J. Hernandez Borrero, Avital Lev, David T. Dicker
Publikováno v:
eLife
eLife, Vol 10 (2021)
eLife, Vol 10 (2021)
Mutations in TP53 occur commonly in the majority of human tumors and confer aggressive tumor phenotypes, including metastasis and therapy resistance. CB002 and structural-analogs restore p53 signaling in tumors with mutant-p53 but we find that unlike
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2c0fcefbdd3d22e54e582c0e5e1ab00
https://doi.org/10.7554/elife.70429
https://doi.org/10.7554/elife.70429
Autor:
Arunasalam Navaraj, Lindsey Carlsen, Shengliang Zhang, Christoph Schorl, Liz J. Hernandez Borrero, Wafik S. El-Deiry, Lanlan Zhou
Publikováno v:
Cancer Research. 81:999-999
Heterogeneity in the p53 response to traditional chemotherapy is recognized but its significance has yet to be exploited in the clinic. Further investigation could provide insight into the relative importance of individual p53 target genes and identi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6247902018d8fc86713a9c3fcf28b31a
https://doi.org/10.1158/1538-7445.am2021-999
https://doi.org/10.1158/1538-7445.am2021-999
Publikováno v:
Cancer Research. 80:6349-6349
Tumor suppressor TP53 is a transcription factor found to be mutated in over 50% of human tumors. Unique to other tumor suppressors, mutations in TP53 result in a stable protein that acquires a gain-of-function activity leading to an aggressive tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f0b295246fe1b088c912c113ae66387
https://doi.org/10.1158/1538-7445.am2020-6349
https://doi.org/10.1158/1538-7445.am2020-6349
Autor:
Rahmat K. Sikder, Prashanth Gokare, Philip Abbosh, Paulo R. Del Valle, Amriti R. Lulla, Xiaobing Tian, Wafik S. El-Deiry, Shengliang Zhang, Liz J. Hernandez Borrero
Publikováno v:
Cancer research. 78(10)
Kim and colleagues reported a p53/p21 complex regulates cancer cell invasion and apoptosis by targeting the Bcl-2 family ([1][1]). Interaction of overexpressed p53 and p21 proteins in p53-null H1299 cells correlated with decreased cell invasion. No c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9bbfe8a03a21ab447b48447351bfef7
https://pubmed.ncbi.nlm.nih.gov/29703718
https://pubmed.ncbi.nlm.nih.gov/29703718
Autor:
Liz J. Hernandez-Borrero, Wafik S. El-Deiry, Shengliang Zhang, Amriti R. Lulla, David T. Dicker
Publikováno v:
Cell cycle (Georgetown, Tex.). 17(5)
P53 tumor suppressor gene mutations occur in the majority of human cancers and contribute to tumor development, progression and therapy resistance. Direct functional restoration of p53 as a transcription factor has been difficult to achieve in the cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28d453af14821f7a43da41de5e34d8de
https://pubmed.ncbi.nlm.nih.gov/28749203
https://pubmed.ncbi.nlm.nih.gov/28749203
Much effort is currently focused on the p53 pathway. p53 is a key tumor suppressor, which is mutated or lost in many human cancers. Restoration of the p53 pathway holds the potential to induce selective cell death in tumor cells without harming norma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61843706dd94e9c297bd841c0a482d0f
https://europepmc.org/articles/PMC5602428/
https://europepmc.org/articles/PMC5602428/
Publikováno v:
Cancer Research. 79:3878-3878
The transcription factor encoding TP53 tumor suppressor gene is mutated in more than half of human cancers. TP53 accounts for therapy resistance and poor patient survival in colorectal and other cancers. Upon cellular stress, p53 protein determines c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f10a66673db70216038030311aad79eb
https://doi.org/10.1158/1538-7445.am2019-3878
https://doi.org/10.1158/1538-7445.am2019-3878
Publikováno v:
Cancer Research. 78:4828-4828
Proapoptotic NOXA protein is a p53 transcriptional target that has been shown to be a crucial mediator of cell death in response to chemotherapy agents. Given the fact that NOXA is downregulated in multiple cancers, induction of this protein by small
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7fd0c8c77aa19b6dd409872f2b4faf66
https://doi.org/10.1158/1538-7445.am2018-4828
https://doi.org/10.1158/1538-7445.am2018-4828
Publikováno v:
Cancer Research. 77:5178-5178
P53 is a transcription factor that becomes stimulated upon genotoxic and cellular stress signals ultimately leading to the transcriptional activation of genes involved in processes such as DNA repair, cell cycle arrest, and apoptosis etc. TP53 is the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb4a120a8daf99fdda8c487f5e6405be
https://doi.org/10.1158/1538-7445.am2017-5178
https://doi.org/10.1158/1538-7445.am2017-5178